Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of PDE3 inhibitor and cytokine in combined treatment of tumors

A cytokine and inhibitor technology, applied in the application field of PDE3 inhibitor and cytokine combined treatment of tumors, can solve problems such as hair loss, immunosuppression, vomiting, etc.

Inactive Publication Date: 2021-02-26
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional chemotherapy drugs are mainly cytotoxic drugs, such as DNA alkylating agents (cyclophosphamide, cisplatin, carboplatin), tubulin inhibitors (such as paclitaxel), metabolic antagonists of DNA synthesis precursors (methotrexate ), topoisomerase II inhibitors (such as etoposide), etc. These drugs target the rapidly proliferating and dividing tumor cells and also inhibit the growth of normal cells, resulting in many serious side effects such as cardiotoxicity, vomiting, hair loss, immunosuppression, and more

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PDE3 inhibitor and cytokine in combined treatment of tumors
  • Application of PDE3 inhibitor and cytokine in combined treatment of tumors
  • Application of PDE3 inhibitor and cytokine in combined treatment of tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0186] Cytotoxicity test

[0187] 1. Digest and count the tumor cells in the logarithmic growth phase, inoculate 3000-5000 / well in a 96-well plate with 50ul medium per well, at a constant temperature of 37°C and 5% CO 2 Cells adhered overnight in an incubator.

[0188] 2. After the cells were firmly attached to the wall, 50 ul of the compounds with the drug concentrations shown in Table 1 were added to each well (where ANA represented Anagrelide, and ZARD represented Zardaverine) and incubated for 72 hours.

[0189] 3. After the drug incubation time is over, first observe the response of the cells to the drug (cell number, cell state) under a microscope, and then add 30uL MTT (5mg / ml in PBS) to each well for 3-5 hours.

[0190] 4. After the MTT incubation is completed, go to the sink and throw out the liquid in the 96-well plate (throw out at one time, try to get rid of the liquid in the plate as much as possible, but do not get rid of the blue-purple crystals in the plate), ...

Embodiment 2

[0204] RTCA experiment

[0205] 1. Add 50ul of the cell culture medium of the cells to be tested in each well of the E-plate, and check the background impedance value

[0206] 2. Add 50ul of culture medium containing 3000-5000 cells to be tested into each well, put it into the detection platform (the detection platform is placed in the cell culture incubator as a whole), and set the program to scan and detect the impedance value every 5 minutes.

[0207] 3. The cells were cultured overnight until the growth curve entered the logarithmic growth phase. Take out the E-plate from the detection table and add 50ul of the compound to be tested to the specified concentration per well (the final concentration of each group is shown in Table 3). After the treatment, put it back into the detection table to detect the cell growth in real time.

[0208] table 3

[0209]

[0210]

[0211] Experimental results

[0212] In the RTCA experiment, the treatment results of each drug group...

Embodiment 3

[0214] The experimental method is basically the same as in Example 2, using TNF-α (10ng / mL), ANA (100nM) and TNF-α (10ng / mL)+ANA (100nM) to process Bel7404, SW1116 cell lines; TNF-α (10ng / mL) mL), ZARD (100nM) and TNF-α (10ng / mL) + ZARD (100nM) to treat Bel7404, SW1116 cell lines.

[0215] Experimental results such as Figure 3A-3B As shown, the results show that ANA, ZARD and tumor necrosis factor TNF-α can play a synergistic effect, and the synergistic anti-tumor effect is significantly better than the single use of PDE3 inhibitor or tumor necrosis factor TNF-α.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a PDE3 inhibitor and a cytokine in combined treatment of tumors. Specifically, the invention provides a pharmaceutical composition, which is characterized in that by comprising: (a) a therapeutically effective amount of a first active ingredient, namely, the PDE3 inhibitor; and (b) a therapeutically effective amount of a second active ingredient,namely, thecytokine. The PDE3 inhibitor and the cytokine have an obvious synergistic anti-cancer effect through combined application and can be used for treating various cancers.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to the application of PDE3 inhibitors and cytokines in combined treatment of tumors. Background technique [0002] Tumor has become the number one killer of human health. According to the American Cancer Society's "2018 Global Cancer Statistics" report, there were about 18.1 million new cancer cases and 9.6 million cancer deaths worldwide in 2018. Tumor treatment has always been an urgent problem for human beings to overcome. Traditional tumor treatment includes three methods: surgery, chemotherapy and radiotherapy. These three treatment methods have made great achievements but also have great limitations. Traditional chemotherapy drugs are mainly cytotoxic drugs, such as DNA alkylating agents (cyclophosphamide, cisplatin, carboplatin), tubulin inhibitors (such as paclitaxel), metabolic antagonists of DNA synthesis precursors (methotrexate ), topoisomerase II inhibito...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K38/19A61K38/21A61K31/519A61P35/00
CPCA61K31/519A61K38/191A61K38/21A61K45/06A61P35/00A61K2300/00A61K31/50A61K31/517A61K38/19
Inventor 俞强安然
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com